StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck vytorin (ezetimibe/simvastatin, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M)

Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b

QuarterlyAnnual
Latest, Q1 2021
41
Period ended Mar 31, 2021
Change on a year earlier
-22.6%
53 in Q1 2020
History
21 quarters
Since Q1 2016
Sources
5
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedVytorin (ezetimibe/simvastatin, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M)Year on yearSource
Q1 2021Mar 31, 202141-22.6%Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Q4 2020Dec 31, 202043-20.4%Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Q3 2020Sep 30, 202047-17.5%Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Q2 2020Jun 30, 202039-48.7%Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Q1 2020Mar 31, 202053-45.4%Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Q4 2019Dec 31, 201954-34.9%Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
Q3 2019Sep 30, 201957-38.0%Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
Q2 2019Jun 30, 201976-51.0%Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
Q1 2019Mar 31, 201997-41.9%Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
Q4 2018Dec 31, 201883-55.4%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q3 2018Sep 30, 201892-35.2%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q2 2018Jun 30, 2018155-14.8%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q1 2018Mar 31, 2018167-30.7%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q4 2017Dec 31, 2017186-37.8%Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
Q3 2017Sep 30, 2017142-48.0%Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
Q2 2017Jun 30, 2017182-37.9%Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗

Breakdown

What makes up vytorin (ezetimibe/simvastatin, legacy pre-organon spin-off) — worldwide sales ($m)

Cite this data

StockData. (2026). Merck Vytorin (ezetimibe/simvastatin, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M), quarterly Q1 2016–Q1 2021 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_vytorin

See every metric in the Merck KPI table. Data updated Oct 26, 2026.